Results 21 to 30 of about 6,882 (175)

AARS1-Mediated H3K27 Lactylation Rewires Glycolysis to Sustain Aggressive and Recurrent Bladder Cancer. [PDF]

Adv Sci (Weinh)
AARS1 drives PI3K–AKT–mTOR‐dependent glycolysis in bladder cancer, promoting lactate accumulation, increased lactylation, H3K27la enrichment at the HK2 promoter, and HK2 transcription. HK2 reinforces glycolysis, sustaining a metabolic–epigenetic program associated with tumor progression, recurrence, and metastasis.
Yuan Q, Song T, He Y, Xia S, Huang Y, He W, Yi Q, Wang Z, Wang P, Huang C, Li L, Yin Z, Cheng F, Yu W.   +13 more
europepmc   +2 more sources

Aplastic Anemia Treated with Eltrombopag during Pregnancy [PDF]

, 2022
Aplastic anemia is a rare blood disorder characterized by pancytopenia and hypocellular bone marrow. In patients with aplastic anemia, pancytopenia sometimes worsens during pregnancy, and relapse of aplastic anemia in pregnancy is common.
Kondo, Tadakazu, Okamoto, Haruko, Kawamura, Yosuke, Taki, Mana, 千草, 義継, 最上, 晴太, 岡本, 葉留子, 近藤, 忠一, Chigusa, Yoshitsugu, Mogami, Haruta, 川村, 洋介, 住永, 優里, 滝, 真奈, Suminaga, Yuri, Mandai, Masaki, 万代, 昌紀   +15 more
core   +2 more sources

Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study. [PDF]

Am J Hematol
ABSTRACT The RACE study (NCT02009747) compared horse antithymocyte globulin (hATG) plus cyclosporine A (CsA) ± eltrombopag as initial immunosuppressive treatment (IST) for severe aplastic anemia. Here we report the final 2‐year analysis of this prospective randomized phase III study.
Risitano AM, Iacobelli S, Kulasekararaj A, van Os M, Terwel SR, Tuffnell J, Piepenbroek B, Griffin M, Halkes CJM, Recher C, Barraco F, Forcade E, Vallejo JC, Drexler B, Mear JB, Trikha R, Gandhi S, Raiola AM, Daenen LGM, de Groot MR, Daguindau E, Nur E, Barcellini W, Russell NH, Terriou L, Paola Iori A, Barberi W, Sureda A, Sánchez-Ortega I, Xicoy B, Jarque I, Cavenagh J, de Fontbrune FS, Frieri C, Munir T, Tjon JML, Tavitian S, Praire A, Clement L, Rabian F, Marano L, Hill A, Palmisani E, Muus P, Marotta S, Cacace F, Laurino M, Passweg JR, Socié G, Mufti GJ, Dufour C, Peffault de Latour R, Severe Aplastic Anaemia Working Party of the EBMT.   +52 more
europepmc   +2 more sources

The Efficacy of Eltrombopag Treatment in Patients who developed Platelet Engraftment Failure after Allogeneic Stem Cell Transplantation: A Single Center Experience

Bezmiâlem Science, 2021
Objective:Persistent thrombocytopenia is a common complication of allogeneic stem cell transplantation (ASCT). Treatment of platelet engraftment failure after ASCT remains controversial. Drugs, such as eltrombopag, are used for this purpose.
Ali ESER, Ayşen TİMURAĞAOĞLU
doaj   +1 more source

Discovery of the anti-angiogenesis effect of eltrombopag in breast cancer through targeting of HuR protein

Acta Pharmaceutica Sinica B, 2020
HuR (human antigen R), an mRNA-binding protein responsible for poor prognosis in nearly all kinds of malignancies, is a potential anti-tumor target for drug development.
Yuying Zhu, Liuqing Yang, Jiazhen Xu, Xiyan Yang, Pengwei Luan, Qianfei Cui, Pei Zhang, Feiyun Wang, Ruixiang Li, Xinyue Ding, Lixian Jiang, Guoqiang Lin, Jiange Zhang   +12 more
doaj   +1 more source

Clinical Care Team’s Guide for Awareness on Risk Assessment of Eltrombopag Complicating Acute Kidney Injury in Relapsed Immune Thrombocytopenic Patients: A Case Report

Medicina, 2023
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder caused by antigen-specific T cells and antiplatelet autoantibodies that inhibit platelet production in the bone marrow or destroy platelets in the spleen.
Eman Mostafa Hamed, Mohamed Hussein Meabed, Ahmed R. N. Ibrahim, Ahmed M. Khalaf, Doaa Mohamed El Demerdash, Marwa O. Elgendy, Haitham Saeed, Tamer M. Mahmoud, Heba F. Salem, Hoda Rabea   +9 more
doaj   +1 more source

Aplastic anaemia treated using eltrombopag in a dog

, 2023
2023 Acuerdos transformativos CRUEA 2-year-old, neutered, female beagle was presented to a referral hospital for investigation of pancytopenia. The patient had a history of recurrent infections and, on previous blood tests, anaemia, leukopenia and ...
Atencia Fernández, Sabela María, Sabela Atencia, Rodríguez Cobos, Alfredo, Alfredo Rodriguez‐Cobos   +3 more
core   +1 more source

Comparison of Splenectomy and Eltrombopag Treatment in the Second-Line Treatment of Immune Thrombocytopenic Purpura

Turkish Journal of Hematology, 2021
Objective: Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by isolated thrombocytopenia. While first-line treatments focus on inhibiting autoantibodies and platelet destruction, second- and third-line treatments ...
Mehmet Can Uğur, Sinem Namdaroğlu, Esma Evrim Doğan, Esra Turan Erkek, Nihan Nizam, Rafet Eren, Oktay Bilgir   +6 more
doaj   +1 more source

Efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia: stage 2 results from a multicenter phase III study

Platelets, 2022
This phase III, randomized, placebo-controlled study conducted in three stages (6-week, randomized, placebo-controlled stage 1; 24-week, open-label stage 2; and continuous extension stage 3) assessed the long-term efficacy and safety of eltrombopag use ...
Xiaofan Liu, Ming Hou, Junmin Li, Jie Jin, Meijuan Huang, Ziqiang Yu, Xiaojun Xu, Xiaohui Zhang, Renchi Yang   +8 more
doaj   +1 more source

EVALUATION OF THE FREQUENCY OF ARTERIAL AND VENOUS THROMBOSIS AND PREDISPOSING FACTORS IN PATIENTS USING ELTROMBOPAG

Hematology, Transfusion and Cell Therapy, 2021
Objective: Eltrombopag is a small molecule thrombopoietin-receptor agonist used orally for the treatment.There is a high risk of thrombosis associated with the use of Eltrombopag.
Derya Deniz Kurekci, Melda Isevi, Engin Kelkitli, Mehmet Turgut   +3 more
doaj   +1 more source